Deep Sedation With Propofol Administered by Electrophysiologists in Atrial Fibrillation Ablation

Sedación profunda basada en propofol y administrada por electrotésofisólogos en la ablation de la fibrilación auricular

To the Editor,

Patient sedation is a fundamental aspect of catheter ablation procedures. In prolonged or painful procedures, such as atrial fibrillation (AF) ablation, the patient may receive “conscious sedation”, which does not prevent involuntary movements or perception of pain, or general anesthetic.¹ The choice of one or the other depends on patient characteristics and anesthetist availability. “Deep sedation” with propofol has been developed as a third alternative in AF catheter ablation.¹⁻⁴ This option can achieve immobility and complete analgesia without the need for intubation or general anesthetic. We describe our experience with this technique.

We prospectively included all patients who underwent AF ablation in our hospital from July 2012 to December 2016. The study was authorized by the local ethics committee. The ablation procedure has previously been described elsewhere.⁵ Briefly, via the right femoral vein, we introduced 1 decapolar catheter up to the coronary sinus, and, via a single transseptal puncture, one

---

REFERENCES


http://dx.doi.org/10.1016/j.rec.2017.06.003
1885-5857/ © 2017 Sociedad Española de Cardiología. Published by Elsevier España, S.L.U. All rights reserved.
3.5 mm irrigated ablation catheter and 1 circular mapping catheter. Patients were anticoagulated with heparin sodium to maintain an activated clotting time of between 250 and 350 seconds. With a CARTO3 navigation system (Biosense Webster), antral ablation of ipsilateral pulmonary vein ablation pairs was performed; radiofrequency was delivered at 35/25 W at 45°, and irrigation at 30/17 mL/min. The aim of ablation was bidirectional block of the pulmonary veins. A nurse administered the “sedation protocol” (Table 1) under the supervision and instruction of the electrophysiologists. The airway was maintained patent with a Guedel airway and continuous oxygen therapy at 2 L/min via nasal prongs. Patient eye protection was passive eyelid closure, held closed with surgical paper tape. In all patients, invasive arterial pressure, heart rate, and oxygen saturation were recorded every 15 minutes throughout the procedure. The “procedure time” was taken as the time from femoral puncture until catheter withdrawal; “sedation time” was from the start of midazolam administration until the end of propofol administration, which was continuous until the activated clotting time was < 250 seconds for the removal of the safety introducers; and “recovery time” was from the end of propofol administration until patients were fit to leave the electrophysiology laboratory to go to their room (conscious and hemodynamically stable). The day after the procedure, patients were given a questionnaire to evaluate the perception of pain and whether they would repeat the same type of sedation in the future, both variables being considered as dichotomous qualitative variables with 2 possible responses (yes/no).

During the inclusion period, 320 AF ablation procedures were performed. The patients’ baseline clinical characteristics are shown in Table 2. The procedure time was 120 ± 20 minutes, and the aim was achieved in all patients. There was 1 major complication, a cardiac tamponade, which was successfully drained, and 2 pseudoaneurysms at the puncture site, which resolved with conservative management. Sedation time was 140 ± 19 minutes and recovery time was 20 ± 5 minutes. Six patients (1.9%) had hypoxemia (oxygen saturation < 90% for more than 20 seconds) requiring manual ventilatory support with a bag valve mask for less than 2 minutes. The other instances of hypoxemia were mild and resolved rapidly with a jaw thrust and temporary reduction in propofol infusion. Forty-five patients (14%) had hypotension (systolic arterial pressure < 90 mmHg for more than 3 minutes), which responded to fluids and adjustment of the propofol infusion. No cases required CARTO3 map reconstruction due to patient involuntary movements. All patients went to a normal hospital ward once the procedure was finished, none reported pain or discomfort during the intervention, and all stated that they would opt for this type of sedation in the future.

Our data demonstrate that for patients undergoing AF ablation, deep sedation with propofol supervised by an electrophysiologist is effective (there are no involuntary patient movements and it avoids pain) and safe (no serious adverse events) and allows the procedure to be performed without the need for general anesthesia. This method of sedation could be very useful in centers without anesthetists and avoids preoperative anesthetic assessment and transfers to the recovery room. Future studies will tell if new drugs, such as dexmedetomidine, used in conscious sedation could be a valid alternative to this type of deep sedation. Since the patient population of this study was selected and relatively young, as happens in AF ablation, the results should not be extrapolated to older patients with advanced heart disease.

Inmaculada Paneque,* Manuel-Ángel Calvo-Calvo,b Carmen Rubio-Guerrero,* Manuel Frutos-López,* Eduardo Arana-Rueda,* and Alonso Pedrotea,*b

*aSección de Arritmias, Servicio de Cardiología, Hospital Universitario Virgen del Rocío, Sevilla, Spain
bDepartamento de Enfermería, Universidad de Sevilla, Sevilla, Spain

*Corresponding author:
E-mail address: pedroteal@hotmail.com (A. Pedrote).

Available online 27 July 2017

REFERENCES
Recurrent Cardiac Fibroelastoma. Is It Really a Benign Tumor?

Fibroelastoma papilar recurrente. ¿Es realmente un tumor benigno?

To the Editor,

Papillary fibroelastomas are the second most common cardiac tumor. These tumors are benign and typically occur in the valvular endocardium, and most present as solitary masses. Only a small percentage cause symptoms. Recurrence of these tumors is exceptional—until now it has not been described in the literature—and for the treatment such cases is unclear.

We present the case of a 32-year-old man who presented with a stroke. Transesophageal echocardiography showed a mobile mass attached to the mitral valve causing mild regurgitation, with no other abnormalities. Three-dimensional transesophageal echocardiography (3D-TEE) confirmed the presence of a 6 × 5 mm round tumor, with a friable appearance, attached to the atrial aspect of the mitral valve, at the free edge of the posterior leaflet (P1), suspicious of papillary fibroelastoma (Figure 1). In addition, electrocardiography showed negative T-waves in the inferior leads, and consequently magnetic resonance was performed, which showed a small midsegment–basal subendocardial infarct of the posterior septum and inferior wall (Figure 1).

With this suspected emboligenic papillary fibroelastoma, the patient underwent cardiac surgery, in which the mass was resected, with valvuloplasty using a pericardial patch. The surgical result was good, with no residual regurgitation. Pathology showed papillary fronds of connective tissue with few cells, covered with a single layer of endothelial cells, findings characteristic of a papillary fibroelastoma (Figure 1).

At follow-up, the patient remained asymptomatic, and transthoracic echocardiograms performed every 6 months showed no abnormalities.

At 2 years postintervention, the patient had sudden-onset low back pain, and renal embolism was diagnosed. Repeat 3D-ETT was performed, which showed a new 4 × 4 mm tumor, with similar characteristics, this time located on the atrial aspect of the anterior leaflet of the mitral valve (A1), just in front of the location of the previous mass (Figure 2).

Given this rapid tumor recurrence and the aggressive presentation on both occasions (stroke, myocardial infarction, and renal embolism), it was decided to perform mechanical mitral valve replacement (Figure 2). Pathology again confirmed that this was a fibroelastoma.

After myxoma, papillary fibroelastoma is the second most common benign cardiac tumor.¹ These tumors originate in the valvular endocardium, mainly in the aortic and mitral valves, although cases have also been described of attachment to the ventricular walls.² They usually present as solitary masses or, rarely,